non-small cell lung cancer
Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance.Â
European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC
The agent is approved for non-small cell lung cancer patients in Europe whose tumors harbor METex14 skipping and who received prior immunotherapy and/or chemo.
Biocartis, AstraZeneca Ink Companion Diagnostic Pact
The agreement includes obtaining US regulatory clearance of a companion diagnostic for Tagrisso, which is used to treat NSCLC patients who carry specific mutations.
In Brief This Week: Agilent Technologies, Mission Bio, EQRx, Center for Breakthrough Medicines
News items for the week of June 13, 2022.
The companies have expanded their partnership to include GE's Fabric technology as they seek to predict response to metastatic non-small cell lung cancer therapies.